ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: ANI set EPS guidance of $9.19–$9.69, above the consensus of $8.79, and revenue guidance of $1.1 billion, in line with expectations.
• Quarterly beat: ANI reported Q1 EPS of $2.05 versus $1.28 expected and revenue of $237.5M versus $207.6M expected, with revenue up 20.5% year-over-year.
• Market and insider activity: ANIP shares rose to $84.36 on elevated volume (792,568 vs. avg 400,455); analysts hold a "Moderate Buy" consensus with an average target of $107.33, while insiders sold ~27,860 shares (~$2.11M) in the past 90 days.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 9.190-9.690 for the period, compared to the consensus EPS estimate of 8.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

ANI Pharmaceuticals Stock Performance

ANIP stock traded up $0.45 on Friday, hitting $84.36. The company's stock had a trading volume of 792,568 shares, compared to its average volume of 400,455. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 25.09 and a beta of 0.46. The firm has a 50 day moving average of $76.82 and a two-hundred day moving average of $81.01. ANI Pharmaceuticals has a 1 year low of $56.71 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analysts' expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The company's quarterly revenue was up 20.5% on a year-over-year basis. During the same period last year, the company earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts predict that ANI Pharmaceuticals will post 7.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 14th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, April 15th. Finally, Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $107.33.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the transaction, the senior vice president directly owned 38,730 shares of the company's stock, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the completion of the transaction, the senior vice president directly owned 84,782 shares of the company's stock, valued at $6,485,823. This represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 27,860 shares of company stock valued at $2,111,581 in the last ninety days. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ANIP. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after acquiring an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after acquiring an additional 423 shares during the period. Jane Street Group LLC acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at $2,706,000. Finally, Norges Bank acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at $625,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.